---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-004911"
form_type: "8-K"
ticker: "ODYY"
cik: "0001626644"
company_name: "Odyssey Health, Inc."
filed_at: "2022-07-13T23:59:59+00:00"
generated_at: "2026-06-24T15:57:09.789605+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Odyssey Health completes Phase I SAD trial for concussion drug PRV-002; moving to MAD phase

## Summary
- Phase I Single Ascending Dosing (SAD) completed with three cohorts; drug PRV-002 safe and well tolerated, no severe adverse events.
- Cohort III (8 healthy volunteers) cleared; Safety Review Committee unanimously approved start of Multiple Ascending Dosing (MAD) Cohort I.
- Intranasal delivery showed low blood levels of PRV-002, supporting targeted brain delivery hypothesis.
- Company planning FDA meeting to present Phase I data; Phase II trial sites and study design under development.
- Global concussion treatment market valued at $6.9B (2020), forecast to reach $8.9B by 2027 (Grandview Research).

## SEC filing metadata
- accession: 0001683168-22-004911
- form_type: 8-K
- ticker: ODYY
- cik: 0001626644
- company_name: Odyssey Health, Inc.
- filed_at: 2022-07-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626644/000168316822004911/0001683168-22-004911-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626644/000168316822004911/odyssey_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-004911
- JSON: https://secwatch.observer/filing/0001683168-22-004911.json
- Plain text: https://secwatch.observer/filing/0001683168-22-004911.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.